Sectors: Pharmaceuticals
Industries: Medical research
Imperial College London has licensed a new cell therapy technology to Australian company SUDA Pharmaceuticals.
The technology, developed by Professor Tassos Karadimitrus and his team at Imperial’s Centre for Haematology, is based on the invariant natural killer T (iNKT) cell, a rare immune cell.
You can read more about the technology, and the license deal, in this longform article by Dr David Silverman.
A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more
Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more
Event date - October 1, 2023
Learn about our programme of events and sign up to be alerted for future events Find out more
Sign up for monthly technology alerts via email, and find other ways to connect with us.
